Clinical trials of cardiovascular devices to treat drug-resistant hypertension should show a clinically significant decrease in blood pressure at six months, as well as a solid safety profile out to five years, according to FDA.
The tips were among those outlined by agency staffers earlier this month, as several major players look to stake a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?